A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 8, 2008, Pages 1076-1083

  Gironi, M ^a,b   Martinelli Boneschi, F ^a   Sacerdote, P ^c   Solaro, C ^d   Zaffaroni, M ^e   Cavarretta, R ^b   Moiola, L ^a   Bucello, S ^a   Radaelli, M ^a   Pilato, V ^e   Rodegher, M E ^a   Cursi, M ^a   Franchi, S ^c   Martinelli, V ^a   Nemni, R ^b   Comi, G ^a   Martino, Gianvito ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d ASL 3 Genovese   (Italy)

^e Hospital of Gallarate   (Italy)

Author keywords

Endorphins; Efficacy; Low dose naltrexone; Opioid receptors; Primary progressive multiple sclerosis; Safety

Indexed keywords

BETA ENDORPHIN; MESSENGER RNA; MU OPIATE RECEPTOR; NALTREXONE; OPRM1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENURESIS; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENETIC VARIABILITY; HEMATOLOGIC DISEASE; HOMOZYGOSITY; HUMAN; IRRITABILITY; KIDNEY FAILURE; LEUKOPENIA; LIBIDO; LOW DRUG DOSE; LUNG CARCINOMA; MALE; MOOD DISORDER; MULTIPLE SCLEROSIS; PAIN; PILOT STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SIDE EFFECT; SPASTICITY; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; ADOLESCENT; AGED; DISABLED PERSON; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; DEPRESSION; DISABLED PERSONS; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NALTREXONE; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; RNA, MESSENGER;

EID: 58149337463     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508095828     Document Type: Article

References (36)

1. Crabtree, BL. Review of naltrexone, a long-acting opiate antagonist. Clin Pharm 1984; 3: 273-280.
2. Gold,MS, Dackis, CA, Pottash, AL, et al. Naltrexone, opiate addiction, and endorphins. Med Res Rev 1982; 2: 211-246.
3. Ibrahim, MM, Porreca, F, Lai, J, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 2005; 102: 3093-3098.
4. Yin, H, Yu, M, Cheng, H, et al. Beta-endorphin prevents collagen induced arthritis by neuroimmuno-regulation pathway. Neuro Endocrinol Lett 2005; 26: 739-744.
5. Stein, C, Schafer, M, Machelska, H. Attacking pain at its source: New perspective on opioids. Nat Med 2003; 9: 1003-1008.
6. Sacerdote, P, Manfredi, B, Gaspani, L, Panerai, AE. The opioid antagonist naloxone induces a shift from type 1 cytokine pattern to type 2 cytokine pattern in balbc/jmice. Blood 2000; 95: 2031-2036.
7. Smith, JP, Stock, H, Bingaman, S, Mauger, D, Rogosnitzky, M, Zagon, IS. Low-Dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol 2007; 102: 1-9.
8. Pugliatti, M, Rosati, G, Carton, H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13: 700-722.
9. Erickson, DL, Lo, J, Michaelson, M. Control of intractable spasticity with intrathecal morphine sulfate. Neurosurgery 1989; 24: 236-238.
10. Rasmussen, NA, Farr, LA. Effects of morphine and time of day on pain and beta-endorphin. Biol Res Nurs 2003; 5: 105-116.
11. Vukusic, S, Confavreux, C. Natural history of multiple sclerosis: Risk factors and prognostic indicators. Curr Opin Neurol 2007; 20: 269-274.
12. Oslin, DW, Berrettini, W, Kranzler, HR, et al. A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546-1552.
13. McDonald, WI, Compston, A, Edan, G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
14. Polman, CH, Reingold, SC, Edan, G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005; 58: 840-846.
15. Kurtzke, JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
16. Bohannon, RW, Smith, MB. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206-207.
17. Thomeé, R, Grimby, G, Wright, BD, Linacre, JM. Rasch analysis of visual analogue scale measurements before and after treatment of patellofemoral pain syndrome in women. Scand J Rehabil Med 1995; 27: 145-151.
18. Krupp, LB, LaRocca, NG, Muir-Nash, J, Steinberg, AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.
19. Beck, AT, Ward, C, Mendelson, M. Beck Depression Inventory (BDI). Arch Gen Psychiatry 1961; 4: 561-571.
20. Martucci, C, Franchi, S, Lattuada, D, Panerai, AE, Sacerdote, P. Differential involvement of Relb in morphine-induced modulation of chemotaxis, NO and cytokine production in murine macrophages and lymphocytes. J Leukoc Biol 2007; 81: 344-354.
21. Ebers, GC. Natural history of primary progressive multiple sclerosis. Mult Scler 2004; 10(Suppl.): S8-S15.
22. Wolinsky, JS, Narayana, PA, O'Connor, P, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24.
23. Stevenson, VL, Miller, DH, Rovaris, M, et al. Primary and transitional progressive MS: A clinical and MRI crosssectional study. Neurology 1999; 52: 839-845.
24. McCarty,MF. "Iatrogenic Gilbert syndrome"- a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007; 69: 974-979.
25. Gironi, M, Furlan, R, Rovaris, M, et al. Beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. J Neurol Neurosurg Psych 2003; 74: 495-497.
26. Viganò, D, Rubino, T, Parolaro, D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 2005; 81: 360-368.
27. Hohmann, AG, Briley, EM, Herkenham, M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999; 822: 17-25.
28. Manzanares, J, Corchero, J, Romero, J, Fernandez-Ruiz, JJ, Ramos, A, Fuentes, JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20: 287-294.
29. Shapira, M, Gafni, M, Sarne, Y. Long-term interactions between opioid and cannabinoid agonists at the cellular level: Cross-desensitization and downregulation. Brain Res 2003; 960: 190-200.
30. Cichewicz, DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004; 74: 1317-1324.
31. Calignano, A, La Rana, G, Giuffrida, A, Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-281.
32. Page, SA, Verhoef, MJ, Stebbins, RA, Metz, LM, Levy, JC. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 2003; 30: 201-205.
33. Baker, D, Pryce, G, Croxford, JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-87.
34. Baker, D, Pryce, G. The therapeutic potential of cannabis in multiple sclerosis. Expert Opin Investig Drugs 2003; 12: 561-567.
35. Zajicek, J, Fox, P, Sanders, H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomized placebo-controlled trial. Lancet 2003; 362: 1517-1526.
36. Docagne, F,Mestre, L, Loría, F, Hernangómez, M, Correa, F, Guaza, C. Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin Ther Targets 2008; 12: 185-195.